Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer

This study is testing how well a medication called lorlatinib works when combined with targeted treatments like radiation or surgery for advanced lung cancer. It focuses on patients whose cancer has a specific genetic feature called an 'ALK rearrangement,' which helps doctors choose more effective, personalized treatments.

This trial is for adults with advanced, stage 4 lung cancer who have the ALK genetic change and have not yet received standard long-term treatments. You must be well enough to handle daily activities and be a candidate for local procedures like surgery or radiation.

Participants will start by taking the medication lorlatinib for 12 weeks to see how the cancer responds. After that, your medical team will determine if adding local treatments, such as surgery or radiation to specific spots, is the right next step for your care.

The study is currently recruiting patients and is taking place in Houston, Texas. You should talk with your oncologist to see if this location is accessible for your specific needs.